Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Inhibitors of growth factor signalling.

A E Wakeling1

  • 1Cancer & Infection Research, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire SK10 4TG, UK. alan.wakeling@astrazeneca.com

Endocrine-Related Cancer
|August 23, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Consensus statement. Workshop on therapeutic resistance in breast cancer: impact of growth factor signalling pathways and implications for future treatment.

Endocrine-related cancer·2005
Same author

Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.

Endocrine-related cancer·2004
Same author

The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.

Endocrinology·2003
Same author

Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.

Annals of the New York Academy of Sciences·2002
Same author

Prospects for combining hormonal and nonhormonal growth factor inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2002
Same author

Modulation of epidermal growth factor receptor in endocrine-resistant, oestrogen receptor-positive breast cancer.

Endocrine-related cancer·2001

Targeted cancer therapies, like trastuzumab, inhibit specific pathways. New drugs targeting epidermal growth factor receptor (EGFR) and other ErbB-associated kinases show promise for breast cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Trastuzumab's success in erbB2-overexpressing breast cancer validates targeted therapy.
  • Epidermal growth factor receptor (EGFR) and other ErbB family kinases are frequently overexpressed in solid tumors.
  • Targeting tyrosine kinase (TK) activity is a key strategy in cancer drug discovery.

Purpose of the Study:

  • To explore novel small molecule inhibitors targeting the EGFR tyrosine kinase.
  • To identify and evaluate new drug candidates for breast cancer therapy based on molecular targets.
  • To investigate ErbB-associated signaling networks and downstream targets for therapeutic intervention.

Main Methods:

  • Development of anilinoquinazoline class inhibitors targeting EGFR tyrosine kinase.

Related Experiment Videos

  • Evaluation of small molecule inhibitors in preclinical and clinical settings.
  • Identification of downstream targets like Ras, MEK, and Src kinase for drug development.

    • Main Results:

    • Anilinoquinazoline inhibitors (e.g., gefitinib, erlotinib) are under evaluation for breast cancer.
    • Prenylation inhibitor AZD3409 and Src kinase inhibitor AZD0530 have entered Phase I clinical trials.
    • These novel agents target key pathways involved in cell division, motility, and invasiveness.

    Conclusions:

    • Targeted inhibition of specific signaling pathways is a viable approach to cancer treatment.
    • New generations of targeted therapies are emerging for breast cancer, addressing diverse molecular mechanisms.
    • Ongoing research into ErbB-associated signaling networks promises further advancements in personalized cancer therapy.